# Endocannabinoid System and Cannabinoid Therapies

Natalie Schmitz, MPA, PharmD, PhD

University of Wisconsin – Madison, School of Pharmacy




### Learning Objectives


- Describe the endocannabinoid system
- Review cannabis botany and US policy
- Discuss therapeutic applications and risks of THC and CBD use
- Identify important considerations for cannabis product selection



# Endocannabinoid (eCB) System


- All vertebrate animals
- Functions: 'relax, eat, sleep, forget and protect'
- eCB has homeostatic roles in:
  - Hunger, feeding, and energy
  - Neural plasticity
  - Neuroprotection
  - Nociception, pain
  - Autonomic tone
  - Immune response
  - Connective tissue repair
  - Human behavior






## Endocannabinoid System

- 3 key components:
  - Cannabinoid Receptors
    - CB1 and CB2
    - Orphan receptors (GPR 19, 55, 119)
  - Cannabinoids
    - Endogenous
      - Anandamide (AEA)
      - 2-arachidonoylglycerol (2-AG)
    - Exogenous
      - Synthetic
      - Phytocannabinoids
  - Enzymes that synthesize and degrade cannabinoids
    - Fatty acid amide hydrolase (FAAH)
    - Monoacylglycerol lipase (MAGL)




#### Regulation of Cell Firing



https://www.leafly.com/news/science-tech/what-is-the-endocannabinoid-system


# Endocannabinoid System

- 1. Endocannabinoids synthesis
- 2. Endocannabinoids diffused retrogradely towards pre-synaptic terminals and bind to G-protein coupled CB1 receptors
- 3. CB1 receptor binding triggers signaling cascades
- CB1 receptor binding results in Gprotein dependent opening of K<sup>+</sup> channels and closing of Ca<sup>2+</sup> channels causing release of neurotransmitters
- 5. Neurotransmitters bind to postsynaptic receptors
- 6. AEA and 2-AG re-enter post- or presynaptic nerve terminals where they are degraded



Abramovici et al. 2018

#### Regulation of Inflammation



())

#### Endogenous vs Exogenous Cannabinoids

#### Endocannabinoids

- Anandamide (AEA) and 2arachidonoylglycerol (2-AG)
- Synthesized at or near the site of action
- Rapidly broken down at the site of action
- Signals are quick and localized

#### Synthetic or Phytocannabinoids

- THC and CBD
- Marinol, Nabilone, Sativex, Epidiolex
- Large volume of distribution
- Metabolized by the liver
- Sustained and global effect



# Terminology

- Cannabis plant family that includes many species
- Cannabinoid chemical compounds found in the cannabis plant
- Cannabidiol CBD
- Hemp variety of the cannabis plant, traditionally used for making ropes and other fibrous materials (< 0.3% THC)</li>
- Marijuana variety of the cannabis plant
- Isolate one pure cannabinoid
- Full spectrum full range of cannabinoids, terpenes, and flavonoids
- Broad spectrum range of cannabinoids, terpenes, and flavonoids but not THC

### What's in the plant?

#### Cannabinoids

- > 100 cannabinoids
- THC
- CBD

# Terpenoids: aromatic, organic compounds found in many plants

- Therapeutic potential
- Myrcene
- Caryophyllene
- Linalool
- Pinene
- Humulene
- Limonene




# Plant Anatomy



https://nationalholistic.com/understanding-the-cannabis-plant-physiology

#### Botany


- Cannabis Sativa
  - Cannabis, Marijuana, Hemp
- Var.
  - C. sativa
  - C. indica
  - C. ruderalis



### Chemistry vs Cultivars

- Cultivar names are applied to domestic plants that have undergone years of breading to express desired traits
  - 'Haze', 'G-13', 'White Widow', 'Hindu Kush'
  - 'Harlequin', 'Cannatonic', 'AC/DC'
- Many are not being properly stabilized leading to batch-to-batch variations
- Cross breeding and bleeding of strains make these names meaningless
- A product's chemical profile is more important that the strain name






# **Conflicting Regulations**


- Cannabis (C-I)
- Epidiolex is FDA approved (C-V)
- By State:
  - Recreational
  - Medicinal
  - CBD only
- 2018 Farm Bill
  - Made CBD from hemp (with < 0.3% THC) legal





https://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx


### Δ-9-tetrahydrocannabinol (THC)



- CB1 and CB2 partial agonist
- Psychoactive
- Anti-inflammatory
- Neuro-protective
- Anti-nausea
- Analgesic (neuropathic, chronic, and cancer pain)
- 11-OH-THC is estimated to be 4x more psychoactive than THC




### Cannabidiol (CBD)



- Non-intoxicant
- No significant affinity to CB1 and CB2 receptors
- Blocks the formation of 11-OH-THC
- Mitigates side effects of THC while improving THC's therapeutic activity
- Most common side effect is diarrhea



# CBD Targets and Action



#### Proposed Pharmacologic Effects of Cannabinoids

Analgesic Antispasmodic Anti-anorectic Antiemetic Neuroprotectant Anti-cancer Antiproliferative Anti-metastatic Anti-angiogenesis Antioxidant Antibacterial Antifungal Antiparasitic

Anti-inflammatory Immunosuppressive Anti-host vs graft Dermatologic Anti-psoriatic Anti-eczema Anti-keratotic Anti-pruritic UV light reducing **Bronchodilatory** Anti-glaucoma Anti-diabetic **Bone-stimulant** 

Anxiolytic Antipsychotic Antidepressant Vasorelaxant Anti-ischemic Anticonvulsant  $\downarrow$  GI motility  $\downarrow$  GI secretions  $\downarrow$  Stomach acid  $\downarrow$  Acid reflux  $\downarrow$  Sleep induction



Target symptom	Tetrahydro- cannabinol	Cannabidiol	
Neuropathic pain	+++	+	
Chemotherapy-induced			
Peripheral neuropathy	++	?	
Nausea or vomiting	+++	Preclinical animal models	
Anticipatory nausea	+	Preclinical animal models	
Appetite stimulation	++	?	
Spasticity or spasms	+++	+	
Inflammation	+	++	
Seizures	+	+++	
Anxiety	+ or –	Simulated situations	
Depression	+ (adjuvant)	Preclinical animal models	
Malignancy			
Preclinical	++	++	
Clinical	+	?	

Evidence of Cannabinoid Efficacy

The Health Effects of Cannabis and Cannabinoids. 2017

#### **Conditions in Clinical Practice**

- Pain (acute pain, chronic inflammatory, neuropathic)
- Mental disorders
- Cancers
- Gastrointestinal disorders
  - Chron's
  - Ulcerative colitis
- Insomnia
- Migraine headaches
- Harm reduction, alternative to opioids
- Spastic disorders

- Autoimmune disorders
- Neurodegenerative disorders
  - Alzheimer's disease
  - Parkinson's disease
  - ALS
- Glaucoma
- Skin diseases
- Epilepsy
- Autism
- Tourette's
- HIV/AIDS



Bridgeman et al. P&T 2007; Hergenrather 2016

# Anti-Inflammatory

#### • Inflammation has a role in many diseases

- Autoimmune disorders
  - Rheumatoid arthritis
  - Multiple sclerosis
- Diabetes (type I and II)
- Atherosclerosis
- Neurodegeneration
  - Alzheimer's disease
  - Parkinson's disease
- Metabolic syndromes
- Neuropathic pain
- Preliminary evidence that CBD modulates the immune cascade to reduce inflammation



# Pain

- Most common condition cited for medical use of cannabis
- Some use it to replace conventional pain medications
- 5 reviews with consistent conclusions modest effect on pain
- Whiting et al 2015
  - 23 RCT in chronic pain (n= 2,454)
  - 22 plant derived THC, 5 synthetic THC
  - 17 neuropathic pain, others included cancer pain, MS, rheumatoid arthritis, musculoskeletal issues, chemotherapy-induced pain
- Suggest that plant-derived cannabinoids increase odds for improvement of pain by ~40%
- Some evidence of dose-dependent effect

# Seizures

- THC and CBD can prevent seizures in animal models
- Epidiolex approved for seizure disorders
- CBD has anti-inflammatory and anticonvulsant properties

# Anorexia and Weight Loss

- CBD has no appetite inducing effects
- Some evidence for oral cannabis in increasing weight in patients with HIV-associated wasting syndrome and anorexia nervosa
- No benefit has been demonstrated on cancer-associated anorexiacachexia syndrome
  - Small studies
  - Short duration
  - Potentially not the optimal dose



# Sleep

- Affect on Sleep disorders
  - THC
    - Decrease time to sleep
    - Conflicting studies on sleep quality
  - THC/CBD combination increased wakefulness
  - CBD
    - Biphasic effect (low doses increased total time of waking, high doses increased sleep time and sedation)
    - Positively affected REM sleep behavior disorder
  - May depend on time of administration
  - Definite conclusions are not possible at this point due to differences in study quality and assessment methods



# **Anxiety and Depression**

- Anxiety
  - Some evidence that CBD improves anxiety symptoms assessed by public speaking test
  - Daily cannabis use is associated with increased anxiety symptoms
- Depression
  - No clinical trials addressing the effects of cannabinoids for major depressive disorder



# Anti-tumor Effects

- THC slowed the growth of lung and breast cancer, and a virus induced leukemia in mice
- Cannabinoids decrease tumor progression through 2 mechanisms
  - Apoptotic death
  - Inhibition of tumor angiogenesis
- One small clinical trial and serval preclinical studies found anti-tumor effects of cannabinoids on gliomas
- Animal studies demonstrate significant reductions in tumor volume
- US Clinical trials of THC+CBD with temozolomide are under progress
- No efficacy studies or reliable case studies are available



# Cancer Risk

- Likely not associate with lung cancer, or head and neck cancers
- Limited evidence of a statistical association between frequent/chronic cannabis smoking and testicular tumors

# **Respiratory Disease Risk**

- Long-term cannabis smoking could cause more frequent bronchitis episodes and worsen respiratory symptoms
  - Vaporizing compared to smoking causes fewer respiratory symptoms
- Evidence that cessation of cannabis improves respiratory symptoms
- Cannabis is not associated with COPD
- May improve airway dynamics with acute use (increased forced vital capacity), but not with chronic use



# Cardiometabolic Risk

- Association with heart attack, stroke, and diabetes is unclear
- Acutely THC can cause tachycardia
- Chronic users may develop bradycardia
- Changes in blood pressure
  - High doses can cause orthostatic hypotension
  - Can acutely increase blood pressure
- Increase risk of angina



# Mental Health Impact

- Association between cannabis use and the development of schizophrenia or other psychoses
- Individuals with schizophrenia and other psychoses, with a history of cannabis use, may be linked to better performance on learning and memory tasks
- Daily cannabis use may increase symptoms in people with bipolar disorder
- Does not increase likelihood of developing depression, anxiety, and PTSD

The Health Effects of Cannabis and Cannabinoids, 2017

# Drug Safety

#### Contraindications

- Acute psychosis or unstable psychiatric condition
- Severe and unstable cardiopulmonary disease
- Pregnant or breastfeeding
- History of alcohol or substance abuse

#### Precautions

- Severe cardiovascular, immunological, liver, or kidney disease
- History of arrhythmias
- Personal history of psychiatric disorder
- Family history of schizophrenia
- Association with hyperemesis syndrome
- Pediatric and elderly patients
- Drug interactions



### Drug Interactions: CYP540 Enzymes

Metabolism

• THC and CBD are metabolized by CYPs 3A4, 2C9, and 2C19

Induction

- THC is a CYP1A2 inducer
  - May reduce serum drug concentrations of clozapine, duloxetine, naproxen, cyclobenzaprine, olanzapine, haloperidol, and chlorpromazine

Inhibition

- THC and CBD CYP3A4
  - May increase serum drug concentrations of macrolides, calcium channel blockers, benzodiazepines, cyclosporine, PDE5 inhibitors, antihistamines, haloperidol, antiretrovirals, and some statins
- THC and CBD CYP2D6
  - May increase serum drug concentrations of SSRIs, tricyclic antidepressants, antipsychotics, beta blockers and opioids

### Drug Interaction Studies

#### Warfarin

- THC and CBD increased warfarin levels
- Frequent cannabis use is associated with increased INR

#### Alcohol

• Alcohol can increase THC levels


#### Theophylline

• Smoked cannabis can decrease theophylline levels

#### CNS depressants

• Additive CNS depressant effects with alcohol, barbiturates, and benzodiazepines

#### Formulations and Routes of Administration





### Route of Administration: Inhalation

- Variable absorption due to inhalation technique
- 20-70% of THC reaches the lungs
- ~ 30% enters systemic circulation
- Shortest onset of action making dose titration possible
- Advantages
  - Simple
  - Effective
- Disadvantages
  - Can contain irritants



### Route of Administration: Oral

#### • Types

- Oral solution
- Capsules
- "Edibles"
- Delayed onset of action
- Longer effect
  - Low and erratic gastrointestinal absorption (< 15%)
  - THC is metabolized into the active metabolite



### Route of Administration: Sublingual

- Types
  - Spray
  - Tincture
  - Lozenge
  - ODT
- Pharmacology
  - Mixed absorption, some drug passes through oral mucosa but other is ingested



### Route of Administration: Topical

- Types
  - Creams
  - Ointments
  - Transdermal patch
- Pharmacology is poorly understood
- There is systemic absorption

### Route of Administration: Rectal

- Stable and bioavailable suppositories have been formulated
- Absorption is ~2x oral administration
- Onset of action ~ 10 minutes
- Avoids metabolism to active metabolite



Route of administration	Action		Amenable to — self-titration
	Onset (min)	Duration (h)	- sen-utration
Smoked	5	2-4	++++
Vaporized	5	2-4	++++
Oral			
Botanical			
Cooked	30-60	8-12	+
Oil	30-60	8-12	+
Теа	30-60	8–12	+
Nabilone	60–90	8-12	+
Dronabinol	30-60	4-6	+
Oromucosal (nabiximols)	15–40	2–4	++

Cannabis Onset and Duration of Action

Cannabinoid Therapies in Oncology – Current Oncology 23: 398 - 406

# **Product Selection**

- Pure cannabis vs crude cannabis
  - Side effects/health risk
  - Cost crude cannabis may be cheaper
  - Lack of control
    - Cannabis content
    - Contaminants
    - Dosing
  - Fewer available routes of administration
    - Crude smoking or ingested
    - Pure inhaled, oral, topical, sublingual, rectal
  - Illegal in some states
- Potential Contamination
  - Fungal and bacterial pathogens
  - Pesticides
  - Heavy metals
- Labeling Accuracy

# Questions?

